首頁
Syndax Pharmaceuticals Inc.

1月 2026Syndax Pharmaceuticals Inc.的市場佔有率分析

健康 > 生物技術和製藥

域名syndax.com

成立年份2005

僱員51 - 200

年度營收$25M - $50M

Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc.（包含公司地區）

syndax.com

查看更多網站流量與參與度資訊

Syndax Pharmaceuticals Inc.截至 1月 2026 的總收入為 25M - 50M

Syndax Pharmaceuticals Inc. 熱門網域產生的總收入

Syndax Pharmaceuticals Inc. 熱門網域 3 年內的總收入

Syndax Pharmaceuticals Inc. 熱門網域的總收入

syndax.com25M - 50M

透過銷售情報查看更多內容

Syndax Pharmaceuticals Inc.的熱門網域總造訪量

了解Syndax Pharmaceuticals Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

syndax.com12.2K

透過銷售情報查看更多內容

Syndax Pharmaceuticals Inc.的熱門網域平均造訪時長

分析Syndax Pharmaceuticals Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

syndax.com00:00:59

透過銷售情報查看更多內容

Syndax Pharmaceuticals Inc.的熱門網域平均頁面瀏覽量

了解Syndax Pharmaceuticals Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

syndax.com2.09

透過銷售情報查看更多內容

Syndax Pharmaceuticals Inc.按網域劃分的熱門競爭對手

1月 2026的熱門類似網站，依相似度排名

visterrainc.com公司名Visterra, Inc.僱員51 - 200總部美國, 馬薩諸塞州, Waltham年度營收$15M - $25M訪問總量2.5K健康 > 生物技術和製藥

使用的熱門技術Syndax Pharmaceuticals Inc.

这些是Syndax Pharmaceuticals Inc.顶级域名使用的行业网站技术

內容管理系統 (2)

WordPress

轉換與分析 (2)

Google Analytics

行動裝置 (2)

Meta Viewport

小工具 (2)

reCAPTCHA

更多技術

9

檢視所有

新聞與訊號來自Syndax Pharmaceuticals Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Syndax Pharmaceuticals, Inc attends event 44th Annual J.P. Morgan Healthcare Conference.Syndax announces presentation at the 44th Annual J.P. Morgan Healthcare Conference.

新聞Syndax Pharmaceuticals, Inc attended event 67th American Society of Hematology (ASH) Annual Meeting on Nov 3rd '25.NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual Meeting.

新聞Syndax Pharmaceuticals, Inc hired Nicholas Botwood BSc as Head of Research and Development (R&D) and Chief Medical Officer on May 12th '25.NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer.